BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Lai RM, Lin S, Wang MM, Li N, Zhou JH, Lin XY, Chen TB, Zhu YY, Zheng Q. Tenofovir alafenamide significantly increased serum lipid levels compared with entecavir therapy in chronic hepatitis B virus patients. World J Hepatol 2023; 15(8): 964-972 [PMID: 37701915 DOI: 10.4254/wjh.v15.i8.964]
URL: https://www.wjgnet.com/1948-5182/full/v15/i8/964.htm
Number Citing Articles
1
Yu-Tong Sun, Qian-Qian Chen. Review on article of effects of tenofovir alafenamide and entecavir in chronic hepatitis B virus patientsWorld Journal of Hepatology 2024; 16(1): 109-111 doi: 10.4254/wjh.v16.i1.109
2
Pin-Nan Cheng, Ming-Lung Yu. Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B: More questions than an answerClinical and Molecular Hepatology 2024; 30(2): 144 doi: 10.3350/cmh.2024.0115
3
Danqing Hu, Peng Wang, Xiaojing Wang, Xue Hu, Da Huang, Weiming Yan, Dong Xi, Meifang Han, Qin Ning, Hongwu Wang. The efficacy of antiviral treatment in chronic hepatitis B patients with hepatic steatosisHeliyon 2024; 10(7): e28653 doi: 10.1016/j.heliyon.2024.e28653